Quick Answer
Taysha Gene Therapies, Inc. reported Cash and Equivalents of $319.77 million for fiscal year 2025.
Taysha Gene Therapies, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $319.77M | +130.0% |
| 2024 | $139.04M | -3.4% |
| 2023 | $143.94M | +63.8% |
| 2022 | $87.88M | -41.1% |
| 2021 | $149.10M | -40.7% |
| 2020 | $251.25M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $297.34M | +88.6% | -4.9% |
| June 30, 2025 | $312.76M | +81.1% | +168.3% |
| March 31, 2025 | $116.59M | -6.0% | -16.1% |
| December 31, 2024 | $139.04M | -3.4% | -11.8% |
| September 30, 2024 | $157.69M | -4.0% | -8.7% |
| June 30, 2024 | $172.74M | +283.2% | +39.3% |
| March 31, 2024 | $123.98M | +95.5% | -13.9% |
| December 31, 2023 | $143.94M | +63.8% | -12.4% |
- Taysha Gene Therapies, Inc. showed an increase of +130.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Taysha Gene Therapies, Inc.’s cash and equivalents has grown by 27.3% (from $251.25 million to $319.77 million).
- The most recent figure is from Taysha Gene Therapies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: